Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1994 Nov;72(5):422–427. doi: 10.1136/hrt.72.5.422

Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.

A Sigurdsson 1, O Amtorp 1, T Gundersen 1, B Nilsson 1, J Remes 1, K Swedberg 1
PMCID: PMC1025608  PMID: 7818958

Abstract

OBJECTIVES--To describe neurohormonal activation in patients with mild or moderate heart failure and how it may be modified by treatment with ramipril. SETTING--Cardiology departments at 24 hospitals in Denmark, Finland, Norway, and Sweden. PATIENTS--223 patients with mild or moderately severe congestive heart failure who were taking diuretics with or without digitalis. DESIGN--Randomised, double bind, multicentre, placebo controlled comparison of ramipril and placebo. Venous blood samples were drawn at rest, before blind treatment, and after 12 weeks of treatment with the study drug. A probability prediction score for mortality derived by stepwise linear discriminant from neurohormone data in the first cooperative north Scandinavian enalapril survival study (CONSENSUS I) was used to assess combined activity of the different neurohormonal systems. RESULTS--Plasma concentrations of atrial natriuretic peptide were raised at baseline but angiotensin II, aldosterone, and noradrenaline concentrations were within normal limits. There was, however, a wide interindividual variation. Plasma noradrenaline concentration and prediction score were higher among patients with class III congestive heart failure according to the New York Heart Association's classification than among patients with class II congestive heart failure (P < 0.05). There was a modest but significant inverse correlation between exercise duration at baseline and plasma noradrenaline concentration (r = -0.21, P = 0.0023), aldosterone concentration (r = -0.14, P = 0.04), and prediction score (r = -0.24, P = 0.0004). Prediction score at baseline was significantly higher among those who died (n = 10) than among survivors (P = 0.03). Angiotensin converting enzyme activity was suppressed and plasma concentrations of aldosterone and atrial natriuretic peptide were reduced after 12 weeks of treatment with ramipril compared with placebo. In patients with the most pronounced neurohormonal activation at baseline (highest third of noradrenaline concentration or prediction score), noradrenaline concentration and prediction score were significantly lower after 12 weeks of taking ramipril compared with placebo. Patients with a prediction score in the highest third at baseline had a higher heart rate than to those in the lowest third (P = 0.003). CONCLUSIONS--Neurohormonal activation is associated with the degree of symptoms and the severity of disease in mild or moderately severe congestive heart failure. Treatment with ramipril attenuates neurohormonal activation. This effect is most pronounced among patients with the highest circulating concentrations of neurohormones before the start of treatment.

Full text

PDF
422

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987 Jan;57(1):17–22. doi: 10.1136/hrt.57.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Broqvist M., Dahlström U., Karlberg B. E., Karlsson E., Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J. 1989 Dec;10(12):1075–1083. doi: 10.1093/oxfordjournals.eurheartj.a059429. [DOI] [PubMed] [Google Scholar]
  3. Chimienti M., Moizi M., Klersy C., Guasti L., Salerno J. A. A modified ajmaline test for prediction of the effective refractory period of the accessory pathway in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1987 Jan 1;59(1):164–165. doi: 10.1016/s0002-9149(87)80094-2. [DOI] [PubMed] [Google Scholar]
  4. Cleland J. G., Dargie H. J., Ball S. G., Gillen G., Hodsman G. P., Morton J. J., East B. W., Robertson I., Ford I., Robertson J. I. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985 Sep;54(3):305–312. doi: 10.1136/hrt.54.3.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cody R. J., Atlas S. A., Laragh J. H., Kubo S. H., Covit A. B., Ryman K. S., Shaknovich A., Pondolfino K., Clark M., Camargo M. J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986 Nov;78(5):1362–1374. doi: 10.1172/JCI112723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cody R. J., Franklin K. W., Kluger J., Laragh J. H. Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril. Am J Med. 1982 May;72(5):791–797. doi: 10.1016/0002-9343(82)90547-2. [DOI] [PubMed] [Google Scholar]
  7. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  8. Curtiss C., Cohn J. N., Vrobel T., Franciosa J. A. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978 Nov;58(5):763–770. doi: 10.1161/01.cir.58.5.763. [DOI] [PubMed] [Google Scholar]
  9. Dzau V. J., Colucci W. S., Hollenberg N. K., Williams G. H. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981 Mar;63(3):645–651. doi: 10.1161/01.cir.63.3.645. [DOI] [PubMed] [Google Scholar]
  10. Eriksson B. M., Persson B. A. Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. J Chromatogr. 1982 Mar 12;228:143–154. doi: 10.1016/s0378-4347(00)80427-2. [DOI] [PubMed] [Google Scholar]
  11. Francis G. S., Benedict C., Johnstone D. E., Kirlin P. C., Nicklas J., Liang C. S., Kubo S. H., Rudin-Toretsky E., Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724–1729. doi: 10.1161/01.cir.82.5.1724. [DOI] [PubMed] [Google Scholar]
  12. Francis G. S., Goldsmith S. R., Cohn J. N. Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J. 1982 Oct;104(4 Pt 1):725–731. doi: 10.1016/0002-8703(82)90003-5. [DOI] [PubMed] [Google Scholar]
  13. Francis G. S., Siegel R. M., Goldsmith S. R., Olivari M. T., Levine T. B., Cohn J. N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985 Jul;103(1):1–6. doi: 10.7326/0003-4819-103-1-1. [DOI] [PubMed] [Google Scholar]
  14. Goldsmith S. R., Francis G. S., Cowley A. W., Jr, Levine T. B., Cohn J. N. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983 Jun;1(6):1385–1390. doi: 10.1016/s0735-1097(83)80040-0. [DOI] [PubMed] [Google Scholar]
  15. Gottlieb S. S., Kukin M. L., Ahern D., Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989 Jun;13(7):1534–1539. doi: 10.1016/0735-1097(89)90344-6. [DOI] [PubMed] [Google Scholar]
  16. Ikram H., Chan W., Espiner E. A., Nicholls M. G. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) 1980 Dec;59(6):443–449. doi: 10.1042/cs0590443. [DOI] [PubMed] [Google Scholar]
  17. Johansen K. B., Marstein S., Aas P. Automated method for the determination of angiotensin-converting enzyme in serum. Scand J Clin Lab Invest. 1987 Jun;47(4):411–414. doi: 10.1080/00365518709168923. [DOI] [PubMed] [Google Scholar]
  18. Kromer E. P., Riegger G. A., Liebau G., Kochsiek K. Effectiveness of converting enzyme inhibition (enalapril) for mild congestive heart failure. Am J Cardiol. 1986 Feb 15;57(6):459–462. doi: 10.1016/0002-9149(86)90772-1. [DOI] [PubMed] [Google Scholar]
  19. Kubo S. H., Cody R. J., Laragh J. H., Prida X. E., Atlas S. A., Yuan Z., Sealey J. E. Immediate converting-enzyme inhibition with intravenous enalapril in chronic congestive heart failure. Am J Cardiol. 1985 Jan 1;55(1):122–126. doi: 10.1016/0002-9149(85)90312-1. [DOI] [PubMed] [Google Scholar]
  20. Levine T. B., Francis G. S., Goldsmith S. R., Simon A. B., Cohn J. N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982 May;49(7):1659–1666. doi: 10.1016/0002-9149(82)90243-0. [DOI] [PubMed] [Google Scholar]
  21. McAlpine H. M., Morton J. J., Leckie B., Dargie H. J. Haemodynamic effects of captopril in acute left ventricular failure complicating myocardial infarction. J Cardiovasc Pharmacol. 1987;9 (Suppl 2):S25–S30. doi: 10.1097/00005344-198700002-00007. [DOI] [PubMed] [Google Scholar]
  22. McGrath B. P., Arnolda L. F. Enalapril reduces the catecholamine response to exercise in patients with heart failure. Eur J Clin Pharmacol. 1986;30(4):485–487. doi: 10.1007/BF00607965. [DOI] [PubMed] [Google Scholar]
  23. Mehta J., Lopez L. M., Wargovich T. Eicosapentaenoic acid: its relevance in atherosclerosis and coronary artery disease. Am J Cardiol. 1987 Jan 1;59(1):155–159. doi: 10.1016/s0002-9149(87)80090-5. [DOI] [PubMed] [Google Scholar]
  24. Nicholls M. G., Ikram H., Espiner E. A., Maslowski A. H., Scandrett M. S., Penman T. Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol. 1982 Apr 21;49(6):1497–1501. doi: 10.1016/0002-9149(82)90367-8. [DOI] [PubMed] [Google Scholar]
  25. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation. 1988 Apr;77(4):721–730. doi: 10.1161/01.cir.77.4.721. [DOI] [PubMed] [Google Scholar]
  26. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992 Jul 11;340(8811):88–92. doi: 10.1016/0140-6736(92)90405-r. [DOI] [PubMed] [Google Scholar]
  27. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992 Jul;20(1):248–254. doi: 10.1016/0735-1097(92)90167-l. [DOI] [PubMed] [Google Scholar]
  28. Remes J., Tikkanen I., Fyhrquist F., Pyörälä K. Neuroendocrine activity in untreated heart failure. Br Heart J. 1991 May;65(5):249–255. doi: 10.1136/hrt.65.5.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Richards A. M., Cleland J. G., Tonolo G., McIntyre G. D., Leckie B. J., Dargie H. J., Ball S. G., Robertson J. I. Plasma alpha natriuretic peptide in cardiac impairment. Br Med J (Clin Res Ed) 1986 Aug 16;293(6544):409–412. doi: 10.1136/bmj.293.6544.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Riegger G. A., Kochsiek K. Vasopressin, renin and norepinephrine levels before and after captopril administration in patients with congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1986 Aug 1;58(3):300–303. doi: 10.1016/0002-9149(86)90066-4. [DOI] [PubMed] [Google Scholar]
  31. Sigurdsson A., Held P., Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J. 1993 Nov;126(5):1068–1076. doi: 10.1016/0002-8703(93)90656-t. [DOI] [PubMed] [Google Scholar]
  32. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990 Nov;82(5):1730–1736. doi: 10.1161/01.cir.82.5.1730. [DOI] [PubMed] [Google Scholar]
  33. Thomas J. A., Marks B. H. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978 Feb;41(2):233–243. doi: 10.1016/0002-9149(78)90162-5. [DOI] [PubMed] [Google Scholar]
  34. Wenting G. J., Man in't veld A. J., Woittiez A. J., Boomsma F., Laird-Meeter K., Simoons M. L., Hugenholtz P. G., Schalekamp M. A. Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. Br Heart J. 1983 Jan;49(1):65–76. doi: 10.1136/hrt.49.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. de Simone G., Devereux R. B., Chien S., Alderman M. H., Atlas S. A., Laragh J. H. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. Circulation. 1990 Jan;81(1):107–117. doi: 10.1161/01.cir.81.1.107. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES